Copyright
©The Author(s) 2018.
World J Cardiol. Jun 26, 2018; 10(6): 41-48
Published online Jun 26, 2018. doi: 10.4330/wjc.v10.i6.41
Published online Jun 26, 2018. doi: 10.4330/wjc.v10.i6.41
Variables | Treatment groups | CLOSE(mean ± SD) or N | CLOSURE I(mean ± SD) or N | PC(mean ± SD) or N | REDUCE(mean ± SD) or N | RESPECT(mean ± SD) or N |
Age (yr) | PFO Closure | 42.9 ± 10.1 | 46.3 ± 9.6 | 44.3 ± 10.2 | 45.4 ± 9.3 | 45.7 ± 9.7 |
Medical therapy | 43.8 ± 10.5 | 45.7 ± 9.1 | 44.6 ± 10.1 | 44.8 ± 9.6 | 46.2 ± 10 | |
Age range (yr) | PFO Closure | 16-60 | 18-60 | < 60 | 18-59 | 18-60 |
Medical therapy | 16-60 | 18-60 | < 60 | 18-59 | 18-60 | |
Male | PFO Closure | 137 | 233 | 92 | 261 | 268 |
Medical therapy | 142 | 238 | 114 | 138 | 268 | |
Smoker | PFO Closure | 68 | 96 | 52 | 63 | 75 |
Medical therapy | 69 | 104 | 47 | 25 | 55 | |
Hypertension | PFO Closure | 27 | 151 | 49 | 112 | 160 |
Medical therapy | 24 | 131 | 58 | 58 | 163 | |
Hyper | PFO Closure | 30 | 212 | 50 | - | 196 |
lipidemia | Medical therapy | 36 | 189 | 62 | - | 195 |
Diabetes mellitus | PFO Closure | 3 | - | 5 | 18 | 33 |
Medical therapy | 9 | - | 6 | 10 | 41 | |
CAD | PFO Closure | - | 6 | 4 | - | 19 |
Medical therapy | - | 4 | 4 | - | 9 | |
Family hx of CAD or stroke | PFO Closure | - | 247 | 53 | - | 136 |
Medical therapy | - | 257 | 40 | - | 109 | |
CHF | PFO Closure | - | 2 | - | 3 | |
Medical therapy | - | 0 | - | 0 | ||
MI | PFO Closure | 0 | 7 | 3 | - | 5 |
Medical therapy | 0 | 5 | 1 | - | 2 | |
Cardiac catheterization | PFO Closure | - | 23 | - | - | - |
Medical therapy | - | 17 | - | - | - | |
Valvular disease | PFO Closure | - | 49 | 8 | - | - |
Medical therapy | - | 45 | 5 | - | - | |
Arrhythmia | PFO Closure | - | 26 | - | - | - |
Medical therapy | - | 19 | - | - | - | |
PTCA | PFO Closure | - | 6 | - | - | - |
Medical therapy | - | 2 | - | - | - | |
PVD | PFO Closure | - | 5 | 3 | - | 5 |
Medical therapy | - | 7 | 2 | - | 1 | |
Stokes-adams syndrome | PFO Closure | - | 4 | - | - | - |
Medical therapy | - | 3 | - | - | - | |
DVT or PE | PFO Closure | 5 | 0 | - | - | - |
Medical therapy | 4 | 4 | - | - | - | |
Migraine | PFO Closure | 67 | - | 47 | - | 195 |
Medical therapy | 78 | - | 38 | - | 186 | |
Pericarditis | PFO Closure | - | 2 | - | - | - |
Medical therapy | - | 3 | - | - | - | |
Cardio | PFO Closure | - | 1 | - | - | - |
myopathy | Medical therapy | - | 0 | - | - | - |
Index cryptogenic stroke | PFO Closure | 238 | 324 | 165 | 441 | - |
Medical therapy | 235 | 329 | 163 | 223 | - | |
Index TIA | PFO Closure | - | 122 | 33 | - | - |
Medical therapy | - | 132 | 42 | - | - | |
TEE with moderate- severe shunt | PFO Closure | - | 250 | 135 | 348 | 385 |
Medical therapy | - | 231 | 112 | 173 | 352 | |
Atrial septal aneurysm > 10 mm | PFO Closure | - | 158 | 47 | 86 | 180 |
Medical therapy | - | 165 | 45 | - | 169 | |
> 1 previous TIA or stroke | PFO Closure | 10 | - | 76 | 68 | 111 |
Medical therapy | 7 | - | 79 | 24 | 112 |
- Citation: Anantha-Narayanan M, Anugula D, Das G. Patent foramen ovale closure reduces recurrent stroke risk in cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials. World J Cardiol 2018; 10(6): 41-48
- URL: https://www.wjgnet.com/1949-8462/full/v10/i6/41.htm
- DOI: https://dx.doi.org/10.4330/wjc.v10.i6.41